Celcuity Q3 2026: Zero Revenue by Design, Launch Already Building

Celcuity reported zero product revenue for the third quarter of 2026, missing the $1.21 million consensus estimate entirely as a function of timing. REVTORPYK (gedatolisib) did not ship until September 30, the final day of the quarter, meaning every dollar of commercial revenue falls into Q4 by default. Investors who stop at the top-line number are misreading the story.

Celcuity posted an adjusted loss of $1.21 per share, beating an estimate of $1.51. SG&A surged to $39.8 million from $12.4 million as the company built out its commercial organization, driven largely by the REVTORPYK launch. R&D rose, and a milestone payment to Pfizer was triggered by the FDA approval, pushing the net loss to $73.34 million for the quarter.

Early commercial indicators are concrete. Seventy-eight percent of the top 36 strategic accounts have already ordered REVTORPYK, and the treatment sites engaged with Celcuity's oncology sales specialists treat 82% of breast cancer patients in the U.S. CEO Brian Sullivan noted that physicians are enthusiastic and that over 90% of commercial and Medicare lives are in health plans that cover the drug, reducing one of the most common friction points for a new oncology launch.

The regulatory pipeline adds another layer of optionality. Celcuity submitted a supplemental NDA to the FDA in Q3 based on the PIK3CA-mutant cohort of its Phase 3 VIKTORIA-1 trial, a filing that would broaden the label well beyond the currently approved wild-type population. Data presented at ESMO 2026 showed a median progression-free survival of 21.5 months for the triplet regimen versus 9.1 months for the comparator in patients without liver metastases, with lower discontinuation due to adverse events.

Celcuity ended the quarter with $642.7 million in cash, cash equivalents, and short-term investments, which management projects will fund operations through 2029. The balance sheet does carry $754 million in convertible notes and a stockholders' deficit, so the runway assumption depends on the launch ramping as expected. Q4 2026 will be the first quarter with a full period of REVTORPYK shipments, making it the real test of whether early ordering translates into sustained commercial demand.